公开(公告)号：WO2019027054A1

公开(公告)日：2019-02-07

申请号：PCT/JP2018/029321

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： ITO, Masahiro ,  SUGIYAMA, Hideyuki ,  KUBO, Osamu ,  KIKUCHI, Fumiaki ,  YASUI, Takeshi ,  KAKEGAWA, Keiko ,  IKEDA, Zenichi ,  MIYAZAKI, Tohru ,  ARIKAWA, Yasuyoshi ,  OKAWA, Tomohiro ,  YONEMORI, Jinichi ,  TOITA, Akinori ,  KOJIMA, Takuto ,  ASANO, Yasutomi ,  SATO, Ayumu ,  MAEZAKI, Hironobu ,  SASAKI, Shinobu ,  KOKUBO, Hironori ,  HOMMA, Misaki ,  SASAKI, Minoru ,  IMAEDA, Yasuhiro

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D487/04 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/513 ,  A61K31/5377 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.